Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phenylbutyrate in Inclusion Body Myositis
NCT04421677Phase 1Completed
- Sponsor
- University of Kansas Medical Center
- Start
- Aug 2020
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sodium phenylbutyrate in inclusion body myositis (IBM), sponsored by University of Kansas Medical Center. Primary endpoint: Incidence of Adverse Events. Started Aug 2020; status: completed.
02
Drugs
sodium phenylbutyrate
03
Conditions
inclusion body myositis (IBM)
Beyond the preview
Go deeper on NCT04421677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04421677.